SCHEMBL2932033

SCHEMBL2932033

CCOC(=O)c1c(N2CCCC2)ccc(N)c1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PRMT1 Q99873 1/20 0.45
ALDH1A1 P00352 8/20 0.44
TSHR P16473 2/20 0.44
PKM P14618 1/20 0.44
HPGD P15428 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
LGMN Q99538 1/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
HSD17B10 Q99714 2/20 0.41
GAA P10253 3/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2924035 0.88 LGMN (0.52) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL2932351 0.82 POLB (0.51) SMN1; SMN2ALDH1A1PKMMEN1KMT2A
SCHEMBL29144718 0.79 ALDH1A1 (0.48) KDM4ESMN1; SMN2NPC1RAB9ANPSR1
SCHEMBL14804765 0.78 KDM4E (0.71) KDM4ESMN1; SMN2NPC1RAB9ANPSR1
SCHEMBL10049116 0.77 KDM4E (0.73) KDM4ESMN1; SMN2NPC1RAB9ANPSR1
SCHEMBL939282 0.73 ALDH1A1 (0.47) KDM4ESMN1; SMN2NPC1RAB9ANPSR1
SCHEMBL2931469 0.72 ALDH1A1 (0.52) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL268116 0.71 IP6K1 (0.61) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL28965465 0.71 TSHR (0.61) KDM4ESMN1; SMN2NPC1ALDH1A1TSHR
SCHEMBL2930533 0.71 CACNA1C (0.45) KDM4ESMN1; SMN2NPC1RAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910314-B1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2010-09-15 EP disclosed
US-20080306064-A1 Benzimidazole Derivatives BROWN LYNDON NIGEL 2008-12-11 US disclosed
EP-1910314-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES Novartis AG (CH) 2008-04-16 EP disclosed
WO-2007009774-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306064-A1 Benzimidazole Derivatives PPARG, PPARD, BRD4 KDM4E 2043/4885SMN1; SMN2 4540/4885NPC1 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.